Lifestyle & Healthslider Most patients on mirikizumab-mrkz for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years by Karine Ayoub February 18, 2025 by Karine Ayoub February 18, 2025 More than 90% of mirikizumab-mrkz-treated patients who were in clinical remission at one year… 0 FacebookTwitterPinterestEmail